Cardio-oncology meets pharmacoeconomics: Cardiovascular toxicity matters in CLL treatment decisions
Year: 2026
Type: article
Abstract: Bruton's tyrosine kinase inhibitors (BTKis) have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), enabling continuous, oral, chemotherapy-free regimens that have gradually replaced chemoimmunotherapy in both frontline and relapsed settings.1,2 This shift represents a paradigm change in CLL therapy, moving away from finite cytotoxic treatments toward targeted, long-term disease management.1,2 Alongside these advances, accumulated clinical experience and dedicated cardio-oncology research have revealed a consistent pattern of cardiovascular toxicities associated with BTK inhibitors (BTKis) --including atrial fibrillation (AF), hypertension (HTN), heart failure, ischemic events, and bleeding ---documented in both clinical trials and real-world cohorts. 1 In this issue of the Portuguese Journal of Cardiology, Figueira et al. 3 make an important and timely contribution by examining the clinical and economic consequences of
Author: Júlia Cristina Toste
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7126207257